Fifty 1 Labs Inc. FITY Archives

FridayAug 22, 2025 10:45 am

QualityStocksNewsBreaks – Fifty 1 Labs, Inc. (OTC: FITY) Partners With ViRx@Stanford on AI-Driven Pandemic Preparedness

Fifty 1 Labs (OTC: FITY), through its subsidiary Fifty1 AI Labs, has entered a strategic partnership with ViRx@Stanford under the “BE READI!” (Biosecurity & Pandemic Preparedness Initiative). The collaboration will leverage Fifty1’s AI platform to repurpose existing drugs into antiviral therapies, accelerating rapid-response treatments for emerging viral threats where vaccines may take a year to deploy. The alliance will launch exploratory AI-driven projects aimed at expanding the antiviral toolkit, drawing on lessons from past pandemics such as COVID-19 and the 1918 influenza, with the goal of strengthening global health security and mitigating future mortality risks. To view the full press…

ThursdayJul 17, 2025 10:20 am

QualityStocksNewsBreaks – Fifty 1 Labs, Inc. (OTC: FITY) and UAV Corp (OTC: UMAV) Announces Strategic Partnership and Intent to Acquire BioSpark AI to Advance Drug Repurposing

Fifty 1 Labs (OTC: FITY) announced a strategic partnership and intent to acquire Vancouver-based BioSpark AI Technologies Inc., a leader in AI and large language model technologies. The alliance merges BioSpark’s literature mining platform with Fifty1’s predictive modeling to extract real-world clinical insights at scale—unlocking overlooked therapeutic patterns for drug repurposing. The partnership will support rapid identification of new formulations focused on performance health and preventative care, with proprietary delivery systems. The move reinforces Fifty1 AI Labs’ vision to lead in AI-powered functional medicine by integrating structured clinical data with advanced Bayesian inference and human-AI collaboration. To view the full…

ThursdayJul 10, 2025 9:10 am

QualityStocksNewsBreaks – Fifty 1 Labs, Inc. (OTC: FITY) and UAV Corp (OTC: UMAV) Completes Historic REVIVE Trial, Sets Stage for Long COVID Breakthrough and Market Expansion

Fifty 1 Labs (OTC: FITY), through its subsidiary Fifty1 AI Labs, LLC, announced the successful completion of the REVIVE Adaptive Platform Trial (NCT06128967), a groundbreaking Phase III study and the largest Long COVID trial to date. Conducted with global partners and top institutions including Stanford and Duke, the randomized, double-blind trial enrolled over 600 participants and demonstrated a clear treatment benefit using repurposed medicines. Powered by FITY’s proprietary AI platform, the trial sets a new standard in drug repurposing and personalized medicine, while supporting the company’s broader strategy to lead the $320.6 billion functional medicine market, pursue strategic acquisitions, and…

TuesdayJul 08, 2025 10:10 am

QualityStocksNewsBreaks – Fifty 1 Labs, Inc. (OTC: FITY) and UAV Corp (OTC: UMAV) Launches Bold AI-Driven Strategy to Reach $50 Million Valuation and Target NASDAQ Uplisting

Fifty 1 Labs (OTC: FITY), a Nevada-based innovator in AI-driven drug repurposing and functional medicine, unveiled a strategic “Game Plan” aimed at achieving a $50 million valuation and uplisting to the OTCQB by Q1 2026, with long-term plans to join the NASDAQ Capital Market. Backed by a $350,000 insider investment and leadership salary deferrals, FITY is advancing its wholly owned subsidiary, Fifty1 AI Labs LLC, with a $1 million R&D initiative to discover repurposed treatments by May 2026. The company will launch a digital platform by July 31, 2025, pursue biotech acquisitions in the $5–10 million range, and host a…

WednesdayApr 30, 2025 9:20 am

QualityStocksNewsBreaks – Fifty 1 Labs, Inc. (OTC: FITY) and UAV Corp (OTC: UMAV) Appoints New CEO, Launches BioSentry Division for Real-Time Biohazard Detection

Fifty 1 Labs (OTC: FITY), a leader in technology and wellness innovation, has appointed Michael Lawson as CEO and Chairman while launching its new BioSentry Division focused on advanced biohazard detection. The division will develop real-time sensor systems using PCR, spectrometry and AI-driven analytics to detect biological, chemical and environmental threats, with applications spanning defense, public health, and industrial safety. The company also announced a strategic partnership with UAV Corp (OTC: UMAV) to integrate the sensors with UAVs and plans to issue a UMAV share dividend to FITY shareholders. Meanwhile, Fifty 1 Labs has opted not to proceed with the…

ThursdayMar 20, 2025 9:35 am

QualityStocksNewsBreaks – Fifty 1 Labs, Inc. (OTC: FITY) Acquires Genetic Networks in $10 Million Stock Deal

Fifty 1 Labs (OTC: FITY) a holding company in the health, wellness, and biotech sectors, has acquired Genetic Networks LLC, a biotech firm founded by Dr. Gennaro D’Urso, for $10 million in common shares. As part of the deal, Dr. D’Urso has been appointed CEO and Chairman, while Brandon Spikes remains President and Director. Genetic Networks, known for its GeneScape™ platform, is actively negotiating multi-million dollar contracts with the U.S. Department of Defense to develop biothreat countermeasures. The acquisition enhances FITY’s biotech capabilities, positioning it for rapid growth in personalized medicine, drug repurposing, and biodefense solutions. To view the full press…

FridayMar 14, 2025 1:05 pm

QualityStocksNewsBreaks – Fifty 1 Labs Inc. (FITY) Achieves Key Milestone in Solidifying Brand, Moves Toward Regaining 15c211 Compliance

Fifty 1 Labs (OTC: FITY), formerly Consumer Automotive Finance Inc. (OTC: CAFI), has successfully completed its name and ticker symbol change, now officially trading as FITY on the OTC market. This marks a significant milestone as the company continues executing its strategic growth initiatives. In addition, the company has responded to a second round of comments in its ongoing efforts to regain compliance with SEC Rule 15c2-11. "We are excited about the progress we've made in solidifying our brand identity and strengthening our market position," said Brandon Spikes, CEO of Fifty 1 Labs. "Finalizing our name and symbol change represents…

Site Search

Company Search

Tag: Fifty 1 Labs Inc. FITY